Traumatic brain injury (TBI) in humans can result in permanent tissue damage and has been linked to cognitive impairment that lasts years beyond the initial insult. Clinically effective treatment strategies have yet to be developed. Transplantation of human neural stem cells (hNSCs) has the potential to restore cognition lost due to injury, however, the vast majority of rodent TBI/hNSC studies to date have evaluated cognition only at early time points, typically b1 month post-injury and cell transplantation. Additionally, human cell engraftment and long-term survival in rodent models of TBI has been difficult to achieve due to host immunorejection of the transplanted human cells, which confounds conclusions pertaining to transplant-mediated behavioral improvement. To overcome these shortfalls, we have developed a novel TBI xenotransplantation model that utilizes immunodeficient athymic nude (ATN) rats as the host recipient for the post-TBI transplantation of human embryonic stem cell (hESC) derived NSCs and have evaluated cognition in these animals at long-term (≥2 months) time points post-injury. We report that immunodeficient ATN rats demonstrate hippocampal-dependent spatial memory deficits (Novel Place, Morris Water Maze), but not non-spatial (Novel Object) or emotional/anxietyrelated (Elevated Plus Maze, Conditioned Taste Aversion) deficits, at 2-3 months post-TBI, confirming that ATN rats recapitulate some of the cognitive deficits found in immunosufficient animal strains. Approximately 9-25% of transplanted hNSCs survived for at least 5 months post-transplantation and differentiated into mature neurons (NeuN, 18-38%), astrocytes (GFAP, 13-16%), and oligodendrocytes (Olig2, 11-13%). Furthermore, while this model of TBI (cortical impact) targets primarily cortex and the underlying hippocampus and generates a large lesion cavity, hNSC transplantation facilitated cognitive recovery without affecting either lesion volume or total spared cortical or hippocampal tissue volume. Instead, we have found an overall increase in host hippocampal neuron survival in hNSC transplanted animals and demonstrate that a correlation exists between hippocampal neuron survival and cognitive performance. Together, these findings support the use of immunodeficient rodents in models of TBI that involve the transplantation of human cells, and suggest that hNSC transplantation may be a viable, long-term therapy to restore cognition after brain injury.
Traumatic brain injury (TBI) in humans can result in permanent tissue damage and has been linked to cognitive impairment that lasts years beyond the initial insult. Clinically effective treatment strategies have yet to be developed. Transplantation of human neural stem cells (hNSCs) has the potential to restore cognition lost due to injury, however, the vast majority of rodent TBI/hNSC studies to date have evaluated cognition only at early time points, typically b1 month post-injury and cell transplantation. Additionally, human cell engraftment and long-term survival in rodent models of TBI has been difficult to achieve due to host immunorejection of the transplanted human cells, which confounds conclusions pertaining to transplant-mediated behavioral improvement. To overcome these shortfalls, we have developed a novel TBI xenotransplantation model that utilizes immunodeficient athymic nude (ATN) rats as the host recipient for the post-TBI transplantation of human embryonic stem cell (hESC) derived NSCs and have evaluated cognition in these animals at long-term (≥2 months) time points post-injury. We report that immunodeficient ATN rats demonstrate hippocampal-dependent spatial memory deficits (Novel Place, Morris Water Maze), but not non-spatial (Novel Object) or emotional/anxietyrelated (Elevated Plus Maze, Conditioned Taste Aversion) deficits, at 2-3 months post-TBI, confirming that ATN rats recapitulate some of the cognitive deficits found in immunosufficient animal strains. Approximately 9-25% of transplanted hNSCs survived for at least 5 months post-transplantation and differentiated into mature neurons (NeuN, , astrocytes (GFAP, 13-16%), and oligodendrocytes (Olig2, 11-13%). Furthermore, while this model of TBI (cortical impact) targets primarily cortex and the underlying hippocampus and generates a large lesion cavity, hNSC transplantation facilitated cognitive recovery without affecting either lesion volume or total spared cortical or hippocampal tissue volume. Instead, we have found an overall increase in host hippo
Introduction
Traumatic brain injury is a serious, debilitating condition that arises from an injury to the head due to blunt or penetrating trauma or from acceleration/deceleration forces. TBI affects upwards of 3.5 million people per year (Coronado et al., 2012) , and there is an estimated 5.3 million people in the United States alone living with permanent, longterm TBI-related disabilities (Griesbach et al., 2015) . However, these numbers likely underestimate the true incidence of TBI due to underreporting of sports-and military-related injuries, and persons who never seek healthcare (Roozenbeek et al., 2013) . To date, treatment options for TBI focus on patient stabilization immediately after injury and subsequent long-term rehabilitative care. Considering that many pharmacologic interventions for TBI have been shown to be ineffective in clinical trials (Xiong et al., 2009; Maas et al., 2010; Lu et al., 2012) , new treatment options must be explored. Stem cell transplantation has the potential to improve functional outcome after central nervous system (CNS) trauma and disease (Cummings et al., 2005; Xu et al., 2006; Ebert et al., 2008; Walker et al., 2009; Zhang and Chopp, 2009; Tetzlaff et al., 2011; Lindvall et al., 2012; Chen et al., 2014a; Experimental Neurology 281 (2016) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Rosser and Svendsen, 2014; Thomsen et al., 2014; Levy et al., 2015; Tsai et al., 2015; Wang et al., 2016) . In the context of TBI, the transplantation of bone-marrow derived mesenchymal/stromal cells has been extensively studied (Li and Chopp, 2009; Aertker et al., 2015) and several clinical trials utilizing human mesenchymal stem cells have been approved and are upcoming (NCT02525432, NCT02416492), ongoing (NCT02028104, NCT01851083) or have been completed (NCT00254722, NCT01575470). However, transplanted human mesenchymal/stromal cells typically do not survive long-term in TBI rodent models (Gold et al., 2013) . Poor cell survival, a rejection response, and/or failure to quantify cell survival can hinder the ability to accurately assess long-term cellular contribution to repair and recovery when either cell replacement and/or long-term transplant-mediated trophic support or immune modulation are putative mechanism(s) of action. Additionally, while there is evidence that suggests that short-term human cell transplant survival is sufficient to promote behavioral recovery after CNS injury and disease (Redmond et al., 2007; Teng et al., 2011; Huang et al., 2014) , a treatment option with the potential for sustained benefits provided by a cell population that survives long-term will be of great use for treating prolonged impairments or impairments that may not manifest for months post-injury.
To enable the evaluation of continuous, long-term repair in animal models, the survival of transplanted cells must be improved. To achieve both increased and prolonged transplanted human cell survival in animal models of CNS injury and disease, the use of immunodeficient rodents (such as the NOD-scid mouse and athymic nude or ATN rat) has been shown to support enhanced transplanted human cell survival (Nasonkin et al., 2009; Anderson et al., 2011; Gowing et al., 2014; Mattis et al., 2014; Xu et al., 2015) . Additionally, transplantation of phenotypically similar CNS-derived neural stem cells into the brain or spinal cord, as opposed to transplantation of foreign blood-or bone marrowderived stem cells, may also improve transplanted cell survival. Therefore, in this study we have utilized immunodeficient ATN rats as our TBI model and transplanted previously characterized hESCderived NSCs that have undergone selective cell sorting to enrich for the stemness marker CD133, a process that was shown to increase both in vitro expansion potential and neuronal differentiation without increasing the risk of teratoma formation in vivo (Haus et al., 2014) .
In addition to achieving improvements in transplanted human cell survival, there is also a need for future TBI and cell transplantation studies to be evaluated at long-term time points (≥2 months). Assessing only early cell survival and behavioral recovery poses two problems: 1) If hNSC engraftment and subsequent integration is integral to behavioral recovery, evaluation at later time points becomes critical as transplanted human cells will likely require at a minimum several months to fully integrate and differentiate into mature neural cell types, and 2) If long-term behavioral improvement is the desired clinical outcome, evaluation of recovery within days to weeks of injury or treatment is not informative for long-term behavioral gains. However, the majority of studies conducted to date assessing the effect of hNSC transplantation into rodent models of TBI have evaluated transplanted cell survival and behavioral recovery only at very early (typically 1-2 weeks) time points post-injury or cell transplantation (Gold et al., 2013) .
To our knowledge, no studies to date have assessed behavioral impairment after cortical impact TBI in ATN rats. Therefore, the first objective of this study was to assess whether and what type of longterm (≥ 2 months) behavioral impairments exist post-TBI in an immunodeficient, ATN model of TBI. In the studies described herein, we have evaluated a broad spectrum of behavioral tasks that could be affected by TBI, including the Morris Water Maze (spatial memory, motor element), Novel Place Recognition (spatial memory), Novel Object Recognition (object memory), Elevated Plus Maze (anxiety), and Conditioned Taste Aversion (classical conditioning). Following this first set of studies that evaluated long-term behavioral performance in ATN rats after TBI, we then tested the hypothesis that intracranial transplantation of human embryonic stem cell-derived neural stem cells can promote long-term histopathological improvement (i.e. reduced lesion volume and/or increased neuronal sparing) and cognitive behavioral recovery after TBI.
Materials and methods

Animal use and controlled cortical impact (CCI) TBI
All animal housing conditions, surgical procedures, and postoperative care was approved by and conducted according to the Institutional Animal Care and Use Committee (IACUC) guidelines at the University of California, Irvine. Adult male athymic nude (ATN) rats (NCI RNU −/− homozygous, 10-11 weeks old; Charles River Laboratories, San Diego, CA) were housed 2 per cage on a 12 hour light/dark cycle with free access to food and water. Unilateral cortical contusions were carried out under isoflurane anesthesia (3%) with rats positioned in a stereotaxic holder (Leica Microsystems Inc.). Injuries were produced using a pneumatic controlled cortical impact device (TBI 0310; Precision Systems and Instrumentation, Fairfax Station, VA) with a 5 mm flat metal impactor tip. The depth of the impact was set at 2.5 mm with a velocity of 4.5 m/s and a dwell time of 500 ms. TBI coordinates were: A/P − 4.5 mm, M/L − 3.6 mm (left cortex, centered over hippocampus); prior to impact, a 6 mm bone flap was removed using a manual trephine.
All animals received lactated ringers (50 ml/kg) subcutaneously immediately after surgery as well as Buprenorphine (0.5 mg/kg) immediately after surgery and for 2 days thereafter. Additionally, due to the immunodeficient nature of ATN rats, an antibiotic (Baytril, 2.5 mg/kg) was administered immediately after surgery and daily for 5 days thereafter.
Human neural stem cell preparation and transplantation
Culture of Xeno-Free CD133+/CD34− Shef6 hNSCs was established at UC Irvine as previously described (Haus et al., 2014) and in accordance with all appropriate hSCRO and IBC protocols. hNSC passage number at the time of transplantation was either passage 7 (P7, "low passage") or passage 27 (P27, "high passage"). At the passages utilized, both Shef6 hNSC lines were N 70% CD133 + , contained b 5% CD34 + expressing cells, exhibited predominantly neuronal differentiation in vitro, and were karyotypically normal. All hNSC and vehicle preparations took place during the day of transplantation/injection. All cells were maintained under normal culture conditions prior to harvesting and collection for transplantation. For hNSC injections, cells were dissociated to single cells using TrypLE and resuspended in X-Vivo 15 to yield 7.5 × 10 4 cells/μl. Vehicle solution consisted of X-Vivo 15 cell culture media. During surgical procedures, all hNSC and vehicle preparations were kept at room temperature. Animals were randomly allocated to different groups: sham (n = 10), vehicle injection (n = 12), and hNSC transplantation (n = 13 Shef6 P27, n = 11 Shef6 P7) and were processed blind to injection cohort. All hNSC and vehicle injections occurred 9 days post-TBI. Previously injured ATN rats were anesthetized with 3% isoflurane and positioned in a stereotaxic holder (Leica Microsystems Inc.). A Dremel rotary tool set at~5000 rpm was used to create injection burr holes. A 5 μl Hamilton syringe (Cat #87930) with a 1″ 30G blunt needle was mounted into an UMP-3 (World Precision Instruments) injector connected to a SYS-Micro4 Controller. A total of four injections of either hNSCs or vehicle were made at the following coordinates: 1) Anterior Hippocampus (A/P −2.50, M/L +1.20, D/V −3.70), 2) Anterior Corpus Callosum (A/P − 2.50, M/L + 1.20, D/V − 2.45), 3) Posterior Corpus Callosum (A/P −5.05, M/L +1.00, D/V −2.90), and 4) Posterior Hippocampus (A/P −5.05, M/L +4.00, D/V −3.90). Cells were first triturated 5 times with a 10 μl pipette then pulled up into the syringe over approximately 10 s. For each injection, the needle was initially lowered an additional 0.15 mm to create a pocket in the brain. For each of the four injection sites, cells were injected at a dose of 6.25 × 10 4 cells (at 7.5 × 10 4 cells/μl) over 2 min (for a total dose of 2.5 × 10 5 cells). Speeds varied relative to total volume, but time of injection remained constant. The needle was raised out of the brain 4 min after injection. The syringe was tested to make sure it was not clogged by ejecting some of the solution into the air manually through the Micro4 controller. Bone wax was applied to seal the burr hole. Animals received lactated ringers (50 ml/kg) subcutaneously immediately after surgery, Buprenorphine (0.5 mg/kg) immediately after surgery and for 2 days thereafter, and Baytril (2.5 mg/kg) immediately after surgery and daily for 5 days thereafter. No immunosuppressant drugs were administered.
Cognitive behavioral analysis
Novel place and object recognition
Behavioral setup and analysis was based on previously published protocols (Acharya et al., 2009 ). All testing was done by experimenters blind to treatment group. Two open field plastic arenas, each measuring 45 × 70 × 70 cm were used for novel place recognition (NPR) and novel object recognition (NOR) testing. The arenas were placed next to each other on the floor of a brightly lit, dedicated behavioral testing room. A video camera was centered on the ceiling above the arenas, and live tracking of the animals was achieved using Noldus Ethovision XT (Noldus Information Technology). For familiarization testing, two identical objects were placed in opposing corners of the open field. For NPR testing, 24 h later one of these objects was moved to an open corner ('novel place'), while the other block remained at its former spatial location ('familiar place'). For NOR testing, 24 h later the object placed in the open corner ('novel place') was removed and replaced with a new, unfamiliar object ('novel object'). Small pieces of white Velcro placed on the undersides of the objects and on the arena floor were used to secure the objects in place during testing. Arenas and objects were cleaned with a 0.1% acetic acid solution between trials to minimize odor cues.
To minimize animal stress, the experimenter handled all animals daily for 1 week before starting NPR testing. For the familiarization phase, rats were placed in the arenas and allowed to explore freely for 5 min. For the retention phases, rats were then returned to their home cages for 24 h before being placed in the test arena again for the test phase, during which they were allowed to explore freely for 3 min. For all phases, the "head direction to zone" function in Ethovision XT was used to track exploration of the objects. A rat was considered to be exploring a block when its head was oriented towards it and its nose was within a 4-cm radius.
Discrimination index, calculated as the ratio of total time spent exploring the novel spatial location or novel object in relation to the familiar spatial location or object (tnovel − tfamiliar / tnovel + tfamiliar) was used as the main dependent measure. Previous research has shown that preference for the novel place can diminish after the first 1-2 min of testing, as the spatial locations become equally familiar to the animals (Mumby et al., 2002) . During our NPR analysis we observed similar results; therefore, data from only the first 2 min of the 3 min test phase was included due to the diminished preference for the novel place during the third minute of testing. Animals that did not explore either object during testing were excluded from analysis.
Morris Water Maze acquisition and reversal
The Morris Water Maze (MWM) consisted of a circular fiberglass pool filled with heated water made opaque by adding non-toxic white paint. A video camera suspended above the pool recorded the animals and video output was recorded by an EthoVision tracking system (Noldus, Leesburg, VA). Visual cues were placed on the four walls surrounding the pool. The water maze protocol included 5 phases: cued learning, spatial acquisition training, probe test, spatial reversal training, and a second probe test. Twenty-four hours prior to spatial acquisition training, the animals were allowed to adapt to the maze for 60 s in a cued learning phase in which the hidden platform was flagged to enable easy location and visual cues were removed from the surrounding walls.
Spatial acquisition training: Twenty-four hours following cued learning, the animals were placed back into the same pool with the flag removed from the hidden platform and visual cues placed back onto the surrounding walls. The animals were then required to swim to find a hidden platform submerged just below the water surface. Training consisted of 4 trials per day for 5 consecutive days. For each trial, the animals were placed into the water facing the pool wall at one of four different starting positions (N, S, E, and W) chosen in semi-random order. During each trial, the rats were allowed to swim freely until they reached the hidden platform and remained for 10 s. Rats that failed to find the hidden platform in 60 s were guided to the platform location. Probe test: Twenty four hours after the final spatial acquisition training trial, the rats were returned to the pool and placed in a new location with the hidden platform absent for 60 s. The rats swim path and number of times crossing the former platform location was recorded.
Spatial reversal training: After the spatial acquisition learning task and initial probe test was completed, a reversal learning protocol was conducted. During reversal learning, the hidden platform was moved to the opposite quadrant. Reversal learning consisted of 5 additional days of training with 4 trials per day, similar to spatial acquisition training. Probe test: Twenty-four hours after the final reversal training trial, the rats were returned to the pool and placed in a new location with the hidden platform absent for 60 s. The rats' swim path and number of times crossing the former platform location was recorded.
Elevated Plus Maze
The Elevated Plus Maze (EPM) consisted of two open and two closed arms fabricated from black plastic (Med Associates Inc.). The apparatus was situated in a dark room, and experiments were recorded using infrared beam detection and an infrared video camera suspended above the plus maze. Live tracking of the animals was achieved using Noldus Ethovision XT (Noldus Information Technology). Each rat was placed in the center of the plus maze facing one of the open arms and allowed to explore for a total of 5 min. Total time spent in the open and closed arms was recorded as well as open and closed arm entries (counted when the center point of the rat crossed into either the open or closed arms). The apparatus was cleaned prior to the introduction of each animal. Rats were tested on the maze in randomized order.
Conditioned Taste Aversion
Behavioral setup and analysis was based on a previously published protocol (Lopez-Velazquez et al., 2007) . Prior to Conditioned Taste Aversion (CTA) testing, the rats were deprived of water for 24 h and given drinking access for 10 min twice a day for 6 days. On Day 7 (acquisition) the water was replaced with saccharin solution (0.1%). 20 min later the rats were injected with LiCl (7.5 ml/kg i.p., 0.2 M) to induce gastric malaise or taste aversion. On Days 8-10 water was given in the morning and afternoon sessions to obtain baseline consumption. Beginning on the morning of Day 11, the water given was substituted with a freshly made 0.1% saccharin solution to test aversion (Day 11) and then extinction (Days 12-22).
Immunohistochemistry
At 20 week post-transplantation, tissue collection and immunohistochemistry was performed as previously described (Hooshmand et al., 2009 ) with minor modifications. Briefly, all animals were anesthetized with a lethal dose of Euthasol (100 mg/kg, i.p.) and transcardially perfused with 50 ml of PBS, followed by 300-400 ml of 4% paraformaldehyde. Brains were carefully dissected and post-fixed overnight in a solution of 4% paraformaldehyde and 20% sucrose in PBS at 4°C, flash frozen at − 65°C in isopentane (2-methyl butane), and stored at −80°C.
For cryosectioning and immunohistochemistry, frozen brains were embedded in Optimal Cutting temperature (O.C.T.) compound (Sakura Finetek USA, Inc.). 30 μm thick coronal sections were cut using a cryostat and sections mounted using a CryoJane tape transfer system (Leica Biosystems, Inc., Buffalo Grove, IL). All tissue sections were antigenretrieved and immunostaining procedures were conducted at room temperature. For 3,3′-diaminobenzidine (DAB) immunohistochemistry, sections were first washed in 0.1 M Tris followed by a 15 min incubation in 0.3% hydrogen peroxide/methanol. For fluorescent immunohistochemistry, wash and blocking steps were performed using PBS rather than Tris. After a brief 0.1% Triton X-100 wash, sections were blocked for 1 h with bovine serum albumin (BSA) and normal serum from the species in which the secondary antibody was raised. Sections were then exposed overnight to the appropriate primary antibody. The primary antibodies used were: monoclonal mouse anti-SC121 (DAB-1:8000, Fluorescent-1:500) (AB-121-U-050, Clontech/Takara), polyclonal rabbit anti-hNestin (1:1000) (ABD69, Millipore), polyclonal rabbit anti-Olig2 (1:500) (AB9610, Millipore), polyclonal rabbit anti-NeuN (1:1000) (ABN78, Millipore), monoclonal mouse anti-APC (CC1) (1:200) (OP80, Calbiochem), polyclonal goat anti-Doublecortin (1:200) (SC-8066, Santa Cruz Biotechnology), and polyclonal rabbit anti-Glial Fibrillary Acidic Protein, GFAP (1:1000) (Z0334, DAKO). The next day, sections were incubated with either fluorescent or biotin-conjugated, purified IgG secondary antibody (1:500, Jackson Immunoresearch) preadsorbed against the species in which the primary was raised, followed by avidin-biotinylated peroxidase complex (ABC) using a Vectastain Elite ABC kit (Vector Laboratories, USA) prepared according to the manufacturer's recommendations (for DAB staining). After several washes, the signal was visualized with diaminobenzidine (DAB) (Vector Laboratories, USA). Sections were mounted onto slides and allowed to dry overnight at 37°C. DAB stained sections were lightly counterstained with Cresyl Violet. Fluorescent stained sections were counterstained with Hoechst 33342 (1:500, Life Technologies). All slides were coverslipped using Depex or Fluoromount-G (SouthernBiotech) mounting medium. Imaging was performed using a Zeiss Imager.M2 Apotome System (Carl Zeiss) and a Zeiss Observer.Z1 Spinning Disk System (Carl Zeiss).
Quantification of histology 2.5.1. Lesion, spared tissue, and ventricle volume analysis
Histological sections comprised of the entire rostral to caudal extent containing cortex (approx. A/P + 5.16 to A/P − 9.36) were used to estimate total brain volume, lesion volume, spared tissue (hippocampus, neocortex) volume, and lateral ventricle volume. Unbiased stereological analysis was performed using a Zeiss Imager.M2 Apotome System (Carl Zeiss) and Microbrightfield Stereoinvestigator version 11.01.1 (MBF Bioscience) Cavalieri probe. A section interval of 1/12 was utilized, placing adjacent sections analyzed at 360 μm apart from each other. Cresyl violet was used to counterstain tissue sections for histological structure identification. Contours were drawn at 2.5 × objective outlining the brain regions of interest and within them counting grids placed, including left/right hemisphere (grid size: 2000 μm), left/right hippocampus (500 μm), left/right neocortex (500 μm), left/right lateral ventricle (350 μm), lesion (1000 μm), and other non-tissue space (350 μm). The described analysis provided an average coefficient of error (CE, m = 1) ratio of b 0.05 for all regions quantified.
Hippocampal neuron survival analysis
Histological sections comprised of the anterior dorsal hippocampus (approx. A/P −1.72 to A/P −4.56) were used to estimate total neuronal survival in both the injured hemisphere dentate gyrus and combined Cornu Ammonis (CA) pyramidal cell layers (consisting of regions CA1, CA2, and CA3) as well as the uninjured hemisphere dentate gyrus. Unbiased stereological analysis was performed using a Zeiss Imager.M2 Apotome System (Carl Zeiss) and Microbrightfield Stereoinvestigator (MBF Bioscience) Optical Fractionator probe. A section interval of 1/12 was utilized, placing adjacent sections analyzed at 360 μm apart from each other. Cresyl violet was used to stain tissue sections for histological structure identification. Contours were drawn at 2.5 × objective outlining the brain regions of interest and neuronal identification and counting was performed at 100 × magnification. Only large Nisslpositive cells containing well defined perikarya and dense ribosomes were counted to limit quantification to neurons. For all regions analyzed, the counting frame utilized was 25 × 25 μm with a grid size of 150 × 150 μm. The dissector height was set at 13 μm with an upper and lower guard zone of 1 μm. The described analysis provided an average coefficient of error (CE, m = 1) ratio for all animals (n = 24-30) of 0.074 (injured DG), 0.075 (injured CA), and 0.057 (uninjured DG).
Transplanted human cell survival analysis
Histological sections comprised of the entire rostral to caudal extent containing cortex (A/P + 5.16 to A/P − 9.36) were used to estimate total human cell survival. Unbiased stereological analysis was performed using a Zeiss Imager.M2 Apotome System (Carl Zeiss) and Microbrightfield Stereoinvestigator (MBF Bioscience) Optical Fractionator probe by an observer blind to treatment group. A section interval of 1/12 was utilized, placing adjacent sections analyzed at 360 μm apart. An anti-SC121 (human cytoplasm) antibody was used to identify human cells and Cresyl violet was used to counterstain tissue sections for histological structure identification. Contours were drawn at 2.5× objective outlining areas of human cell engraftment, and human cell identification and counting was performed at 63 × magnification. The counting frame utilized was 50 × 50 μm with a grid size of 200 × 200 μm. The dissector height was set at 12 μm with an upper and lower guard zone of 1 μm. The described analysis provided an average coefficient of error (CE, m = 1) ratio for all hNSC transplanted animals (n = 22) of 0.23.
Transplanted human cell fate analysis
Analysis was performed using a Zeiss Imager.M2 Apotome System (Carl Zeiss) and Bitplane: Imaris Scientific 3D/4D Image Processing and Analysis (Bitplane AG). A section interval of 1/24 was utilized, placing adjacent sections analyzed at 720 μm apart from each other. Co-localization was performed using either antibodies specific for neurons (NeuN), astrocytes (GFAP), oligodendrocytes (Olig2), and undifferentiated cells (Nestin) along with an anti-SC121 (human cytoplasm) antibody. Hoechst 33342 was used as a nuclear counterstain. To estimate the approximate number of cells of each fate for each animal, a minimum of 3 semi-random images containing at least 10 human cells were analyzed. Each fate group consisted of 4-6 animals.
Statistical analysis
All behavioral, histological, and stereological analyses were performed by experimenters blinded to the experimental groups. Statistical analyses were performed using Prism (Version 6.0b Software). Behavioral data for tasks comparing sham and TBI animals were Fig. 1 . Controlled cortical impact TBI imparts long-term spatial memory impairments in immunodeficient ATN rats. Between 9 and 16 weeks post-injury (WPI), (A) animals were assessed for cognition via the spatial memory tasks Novel Place Recognition (NPR) and the Morris Water Maze (MWM), as well as the non-spatial memory task Novel Object Recognition (NOR) and emotional/anxiety-related tasks such as the Elevated Plus Maze (EPM) and Conditioned Taste Aversion (CTA). (B) TBI animals (n = 11) exhibited a significant 24-hour hippocampaldependent NPR deficit during the first 2 min of testing (one-tailed t-test t19 = 3.93, P b 0.001) when compared to sham animals (n = 10) that was not significantly different from zero (TBI, two-tailed t-test t10 = 1.25, P = 0.24). (C) There was no difference between TBI (n = 12) and sham (n = 10) groups as assessed via the 24-hour hippocampalindependent NOR task (one-tailed t-test t20 = 0.51, P = 0.31). (D) MWM acquisition analysis revealed that on Days 2-5 TBI animals had significantly increased escape latencies finding the hidden platform relative to sham animals. Two-way repeated measures ANOVA was significant for trial day (P b 0.0001) and group (P b 0.001), but not for trial × group interaction (P = 0.06). (E) On Day 6, a Probe Trial revealed that TBI animals spent significantly less time in the target quadrant compared to sham animals (one-tailed t-test t20 = 1.83, P b 0.05). (F) The platform location was then moved to a new location to test reversal learning. MWM reversal analysis revealed that on Days 9-11, TBI animals had significantly increased escape latencies finding the hidden platform relative to sham animals. Two-way repeated measures ANOVA was significant for trial day (P b 0.0001), group (P b 0.0001), and trial × group interaction (P b 0.01). (G) On Day 12, a Probe Trial revealed that TBI animals spent significantly less time in the target quadrant compared to sham animals (onetailed t-test t20 = 2.55, P b 0.01). *P b 0.05, **P b 0.01, ***P b 0.001. Data are presented as mean ± s.e.m.
analyzed via either unpaired one-tailed (NPR, NOR, MWM Probe, EPM) or multiple (CTA) t-tests or via a repeated measures two-way ANOVA (MWM Acquisition and Reversal), unless otherwise stated in the results section. t-Test results reported as tdf = t-score, P value. For behavioral tasks comparing sham, TBI + vehicle, and TBI + hNSCs, analysis was performed using either unpaired two-tailed t-tests (NPR), repeated measures two-way ANOVA (MWM Acquisition and Reversal), or Pearson Correlation (MWM Slope) analysis. All stereological quantifications were analyzed via unpaired two-tailed t-tests. Errors are the standard error (SEM) of averaged results. Significance was defined as at least P b 0.05 for all statistical analyses.
Results
Immunodeficient rats exhibit long-term cognitive impairment following TBI
To improve the long-term survival of transplanted hNSCs, we utilized immunodeficient ATN rats as hNSC recipients. Because zero studies to date have assessed the behavioral response of immunodeficient ATN rats to TBI, multiple cognitive measures were evaluated at delayed (N 2 months) time points post-injury ( Fig. 1) , including: hippocampal-dependent spatial memory (Novel Place Recognition, Morris Water Maze), non-spatial memory (Novel Object Recognition), emotional/anxiety-related behavior (Elevated Plus Maze), and classical conditioning (Conditioned Taste Aversion).
Spatial memory deficits are a hallmark of hippocampal injury, and in our study, the injury location was centered on the cortex directly overlying the dorsal hippocampus. To verify the presence of hippocampaldependent spatial memory deficits, we measured cognition on two separate measures, Novel Place Recognition (NPR) and the Morris Water Maze. On both of these measures, ATN TBI animals displayed long-term cognitive impairment, performing significantly worse than sham animals at N2 months post-injury. First, cognitive function after TBI was evaluated using the NPR task which measures the amount of time an animal spends exploring an object located in a novel location compared to an identical object located in a familiar position. Our results demonstrate that ATN TBI exhibited spatial memory impairment via a decrease in novel location exploration (TBI vs. sham: P b 0.001; Fig. 1B) . Additionally, hippocampal-dependent spatial memory deficits were detected in ATN TBI animals on a second task, the Morris Water Maze (MWM). MWM latency to platform assessment during both the acquisition (Fig. 1D ) and reversal ( Fig. 1F ) learning phases revealed deficits in ATN TBI animals on spatial target location memory as these animals had significantly increased latency to platform times relative to sham animals. Furthermore, probe trial analysis resulted in similar findings with ATN TBI animals spending less time in the target quadrant during both the acquisition (TBI vs. sham: P b 0.05; Fig. 1E ) and reversal (TBI vs. sham: P b 0.01; Fig. 1G ) learning phases, indicating that ATN TBI animals did not remember the location of the platform as well as shams.
TBI ATN rats were also assessed behaviorally on tasks that measure non-spatial memory, or on tasks that measure emotional/anxietyrelated behavior or classical conditioning. Previous findings suggest that non-hippocampal or non-spatial memory impairments are present after TBI, however definitive long-term studies in a controlled cortical impact (CCI) model of TBI have not been conducted in either immunosufficient or immunodeficient animal models. Accordingly, we measured non-spatial memory via the Novel Object Recognition (NOR) task, emotional/anxiety-related behavior via the Elevated Plus Maze (EPM), and classical conditioning via Conditioned Taste Aversion (CTA). Our results indicate that CCI TBI at the severity parameters utilized did not create any apparent long-lasting non-spatial, emotional/ anxiety-related, or classical conditioning-related behavioral impairments. No statistically significant differences were found between ATN TBI and sham operated animals in novel object exploration times relative to a familiar object in the NOR task (TBI vs. sham: P = 0.31; Fig. 1C) . Additionally, no differences were found between ATN TBI and sham animals in the amount of time spent in the open arms of the EPM (TBI vs. sham: P = 0.10; Fig. 2A ) or in the number of entries into the open arms (TBI vs. sham: P = 0.08; Fig. 2B ). Furthermore, no significant differences were demonstrated between ATN TBI and sham operated animals on the CTA task (Fig. 2C) , which was employed as an additional measure of classical conditioning to determine if TBI animals would exhibit impairment in associating a noxious event (LiCl-induced gastric malaise associated with saccharin consumption) with an everyday activity (water/saccharin consumption). Finally, although no explicit motor function tasks were performed in this study, ATN TBI and sham operated animals exhibited no differences in either MWM swim speed or distance traveled during the MWM or EPM tasks (data not shown), suggesting long-term motor function was not impaired by TBI.
Together, these results suggest that following a single, moderateto-severe unilateral CCI TBI to the hippocampus and overlying cortex, immunodeficient ATN rats exhibit long-term hippocampaldependent spatial memory deficits (NPR, MWM). In contrast, ATN performance on non-spatial or non-hippocampal-dependent memory tasks (NOR, EPM, CTA) remains indistinguishable from sham when tested at time points N2 months post-TBI.
hNSC transplantation improves long-term cognitive recovery following TBI
We next sought to determine whether hNSC transplantation could improve cognitive performance following TBI. To test this hypothesis, Xeno-Free CD133-enriched hNSCs were transplanted 9 days post-TBI into 4 sites (anterior medial corpus callosum, posterior medial corpus callosum, anterior dorsal hippocampus, posterior dorsal hippocampus) on the contralateral (uninjured) hemisphere of immunodeficient ATN rats. Following transplantation, animals were assessed behaviorally using the same hippocampal-dependent spatial memory tasks as assessed previously (NPR, MWM).
In the NPR task at 8-weeks post-transplant (WPT), ATN TBI animals receiving vehicle injections performed significantly worse compared to sham animals (TBI + vehicle vs. sham: P b 0.01; Fig. 3B ). Transplantation of high passage (P27) CD133-enriched hNSCs rescued this performance deficit as animals receiving high passage hNSCs performed significantly better than ATN TBI animals that received vehicle injection only (TBI + Shef6 P27 hNSCs vs. TBI + vehicle: P b 0.05; Fig. 3B ). Furthermore, analysis of ATN TBI animals transplanted with high passage Shef6 hNSCs demonstrated a discrimination index that was statistically indistinguishable from sham-operated ATNs on the NPR task (TBI + Shef6 P27 hNSCs vs. sham: P = 0.11; Fig. 3B ). However, ATNs transplanted with low passage (P7) CD133-enriched hNSCs did not exhibit significantly improved cognition post-TBI when compared to vehicle injected ATN TBI animals (TBI + Shef6 P7 hNSCs vs. TBI + vehicle: P = 0.07; Fig. 3B ), suggesting possible differences in behavioral rescue potential exist within the same cell line at different passage numbers.
Following TBI, ATN rats also demonstrated spatial memory impairment on the MWM task. However, hNSC transplanted ATNs did not demonstrate overtly improved cognition as measured by the amount of time (latency) needed to reach the submerged platform over five consecutive days of either acquisition learning (Fig. 3C ) or reversal learning (Fig. 3E) as analyzed by a two-way repeated measures ANOVA. However, when the animals intra-group learning curves were assessed over each of the 5 day learning and reversal trials and plotted as group learning slopes (Rekha et al., 2009 ), a significant shift towards hNSC transplant-mediated cognitive improvement emerged. Whereas during the acquisition learning phase all groups exhibited negative (improved) learning slopes (P b 0.001; Fig. 3D ), in the reversal learning phase, ATN TBI animals receiving vehicle injection exhibited a group learning slope that was statistically equal to zero, indicative of a failure to learn the new platform location (P = 0.36; Fig. 3F ). In contrast, hNSC transplantation appeared to ameliorate this reversal relearning impairment as demonstrated by the negative learning slopes for both sham and low (P7) passage hNSC (P b 0.001; Fig. 3F ) as well as high (P27) passage hNSC (P b 0.01; Fig. 3F ) transplanted animals, further demonstrating that ATN TBI animals transplanted with hNSCs are better able to learn novel locations. No differences were observed in Probe trials for either the acquisition or reversal learning phases, regardless of group (data not shown).
hNSC transplantation improves host hippocampal neuron survival without modification of lesion or total spared tissue volumes
Because hNSC transplantation in our study improved hippocampaldependent spatial memory, we sought to determine whether a histological correlate to behavioral recovery existed. First, to quantitatively assess the long-term impact of both TBI and the subsequent transplantation of hNSCs on lesion size, total spared tissue volume, and ventricle volume, detailed stereological analysis was performed using the Cavalieri method (Fig. 4) . Stereological analysis confirmed the presence of a unilateral lesion cavity occupying primarily somatosensory, motor, and visual cortex regions as well as the underlying corpus callosum and hippocampus ( Fig. 4A-B) on the side of impact. No statistical differences in cortical or hippocampal volumes on the uninjured hemisphere were found for any group when compared to sham animals, confirming the unilateral nature of the injury (data not shown). Following hNSC transplantation, lesion volumes in both the low and high passage hNSC groups remained unchanged compared to ATN TBI animals given vehicle injection (Fig. 4C) , suggesting that hNSC transplantation in our study did not decrease lesion size.
Spared tissue and ventricle volume was also assessed. In the hemisphere ipsilateral to injury, both cortical (TBI + vehicle vs. sham: P b 0.01; Fig. 4D ) and hippocampal (TBI + vehicle vs. sham: P b 0.001; Fig. 4E ) tissue volumes decreased significantly post-TBI, with no volume differences detected between hNSC transplanted and vehicle injected animals. Along with cortical and hippocampal tissue loss, significant ventricle enlargement post-TBI was also detected (TBI + vehicle vs. sham: P b 0.01; Fig. 4F ), in some cases increasing in volume up to three-fold, with hNSC transplantation facilitating a downwards, but not statistically significant, trend in ipsilateral ventricular volume. Taken together, these results demonstrate that TBI at the parameters utilized leads to the formation of a persistent lesion cavity as well as decreased cortical and hippocampal tissue volume and ventricular enlargement in the hemisphere ipsilateral to injury. hNSC transplantation did not significantly alter any of these volumetric outcome measures, yet still managed to effect behavioral recovery, suggesting the presence of an alternative mechanism(s).
Volumetric quantification of affected brain regions after injury provides an important global view of histological outcome. However, subtle changes at the cellular level, such as increased host neuron survival, may be missed with this method. We therefore tested if hNSC transplantation affects long-term host hippocampal neuronal survival after TBI via stereological assessment of hippocampal neuronal survival in both the dentate gyrus (DG) and combined pyramidal cell layers (CA1, CA2, CA3; referred to as CA). In this study, ATN TBI animals that received vehicle injection had significantly fewer hippocampal neurons when compared to sham animals in both the DG (TBI + vehicle vs. sham: P b 0.001; Fig. 5B ) and CA (TBI + vehicle vs. sham: P b 0.0001; Fig. 5C ) regions ipsilateral to injury. Transplantation of high passage (P27) Shef6 hNSCs rescued host neuronal loss in both the DG (TBI + Shef6 P27 hNSCs vs. TBI + vehicle: P b 0.05; Fig. 5B ) and CA (TBI + Shef6 P27 hNSCs vs. TBI + vehicle: P b 0.05; Fig. 5C ) regions. No differences were found in host neuron survival on the uninjured (non-impacted side) DG for any TBI group compared to sham animals (data not shown). ATN TBI animals that received low passage (P7) Shef6 hNSCs demonstrated a non-significant trend towards increased host neuron survival in these same regions. In parallel, correlation analysis revealed positive relationships between both host DG neuron survival (Pearson r = 0.70, P = 0.0003; Fig. 5D ) and host CA neuron survival (Pearson r = 0.64, P = 0.001; Fig. 5E ) with performance on the NPR task, suggesting a strong relationship between hippocampal neuron survival and cognitive performance.
Transplanted hNSCs survive long-term and differentiate into cells of all three neural lineages
A major issue that exists in studies transplanting human cell populations into rodent models of TBI is low overall graft survival, likely due to human-to-rodent xenograft histocompatibility issues and graft rejection. Immunodeficient ATN rats, which are both T-and B-cell deficient, were therefore used in our study to limit the graft rejection response. At 20-weeks post-transplantation, surviving hNSCs (SC121+) exhibited engraftment throughout the host brain, extending into ventral hippocampal and ventral/medial cortical regions as well as occasionally crossing into the injured (non-transplanted) hemisphere (Fig. 6A, D-F) . Of the initial 250,000 hNSCs transplanted 9-days post-TBI, 21,762 ± 10,415 (or 8.7% ± 4.2) high passage P27 CD133-enriched hNSCs and 62,201 ± 17,397 (or 24.9% ± 7.0) low passage P7 CD133-enriched hNSCs survived long-term (Fig. 6B) . However, correlations of transplanted hNSC survival with cognitive improvements were not statistically significant (Fig. 6C) . Overall, while the total transplanted hNSC survival estimates in this study may seem low in comparison to that typically observed when using immunodeficient animals for human cell transplantation studies in a variety of neurological disease and injuries (Anderson et al., 2011) , the extent of transplanted cell survival in this study demonstrates a dramatic Fig. 3 . Transplantation of hNSCs improves cognitive behavioral outcomes after TBI. Between 8 and 12 weeks post-transplantation (9-13 weeks post-TBI), (A) animals were assessed for improvements in cognition via both NPR and MWM. (B) On the NPR task, TBI animals given vehicle injections only (n = 11) performed significantly worse than sham animals (n = 10, two-tailed t-test t10 = 4.27, P b 0.01). TBI animals that received high passage (P27) hNSCs (n = 11) exhibited a significant increase in their novel place exploration ratio during the first 2 min of testing as compared to TBI animals that received vehicle injections only (two-tailed t-test t20 = 2.58, P b 0.05). TBI + Shef6 P27 hNSC animals were indistinguishable from sham animals (two-tailed t-test t10 = 1.76, P = 0.11) and significantly different from zero (two-tailed t-test t10 = 2.78, P b 0.05). TBI animals given low passage (P7) hNSCs (n = 10) did not exhibit increased exploration compared to vehicle injected TBI animals (two-tailed t-test t19 = 1.93, P = 0.07) and performed significantly worse than sham animals (n = 10, two-tailed ttest t9 = 2.63, P b 0.05). (C) Analysis of MWM acquisition escape latency revealed that on Days 2-5, TBI animals given vehicle injection or hNSCs had significantly increased escape latencies finding the hidden platform relative to sham animals. Two-way repeated measures ANOVA was significant for trial day (P b 0.0001), group (P b 0.0001), and trial × group interaction (P b 0.05). No significant differences were detected between TBI animals given vehicle injection only and TBI animals given hNSCs (P27 or P7). (D) Analysis of the slope of acquisition via linear regression revealed significantly non-zero slopes for all groups during MWM acquisition (P b 0.001). (E) MWM reversal escape latency analysis revealed that on Days 7-11, TBI animals given vehicle injection or hNSCs had significantly increased escape latencies finding the hidden platform relative to sham animals. Two-way repeated measures ANOVA was significant for trial day (P b 0.0001) and group (P b 0.0001), but not for trial × group interaction (P = 0.11). No significant differences were detected between TBI animals given vehicle injection only and TBI animals given hNSCs (P27 or P7). (F) Analysis of the slope of acquisition via linear regression revealed significantly non-zero slopes for sham and TBI animals given Shef6 P7 (P b 0.001) or Shef6 P27 hNSCs (P b 0.01) during MWM reversal, however TBI animals given vehicle injection only were statistically indistinguishable from zero (P = 0.36). All data is from analysis conducted 20 weeks post-hNSC transplantation/vehicle injection. improvement over previous reports of transplanted human neural cell survival specifically in rodent models of TBI (Gold et al., 2013) .
Previously, we have found that when transplanted into a naïve immunodeficient host, the cell population used in this study differentiates predominantly into neurons (Haus et al., 2014) . Similarly, cell fate analysis in this study demonstrated that the predominant terminal fate of transplanted hNSCs was neuronal, with 18.6 ± 4.1% of high passage (P27) Shef6 hNSCs and 37.6 ± 2.0% of low passage (P7) Shef6 hNSCs differentiating into NeuN + neurons (Shef6 P27 vs. Shef6 P7: P b 0.01; Fig. 7A-B) . However, a smaller percentage of both astrocytic (GFAP) (Shef6 P27, 13.2 ± 3.4%; Shef6 P7, 15.8 ± 3.2%; Fig. 7C-D) and oligodendroglial (Olig2) (Shef6 P27, 11.3 ± 1.7%; Shef6 P7, 13.1 ± 2.5%; Fig. 7E-F) differentiation was found to be present, suggesting that the TBI microenvironment may influence the in vivo differentiation potential of transplanted embryonic-derived hNSCs. Additionally, a significant portion of transplanted hNSCs remained in an undifferentiated (Nestin +) state, even at 20-weeks post-transplantation (Shef6 P27, 9.7 ± 6.3%; Shef6 P7, 23.9 ± 5.3%; Fig. 7G-H) .
Discussion
Validating long-term cognitive deficits in an immunodeficient rodent model of TBI
TBI research in animal models to date has primarily focused on short term (hours to days) histological and behavioral outcomes (Marklund and Hillered, 2011; Xiong et al., 2013) . While such studies may be informative for assessing the acute response to various forms of intervention, Representative histological section depicting extent of long-term damage resulting from CCI-TBI. Volumetric analysis of (C) lesion volume demonstrates significant lesion formation in all TBI groups when compared to sham animals (two-tailed t-test, P b 0.0001) with no change in lesion size as a result of hNSC transplantation. As a result of TBI, there is (D) a significant reduction in ipsilateral cortical tissue volume in vehicle injected animals when compared to sham (two-tailed t-test t5 = 5.86, P b 0.01), (E) a significant reduction in ipsilateral hippocampal tissue volume in vehicle injected animals when compared to sham (two-tailed t-test t5 = 7.74, P b 0.001) as well as (F) a significant increase in ipsilateral lateral ventricle volume in vehicle animals when compared to sham (two-tailed t-test t5 = 6.18, P b 0.01). hNSC transplantation did not alter either cortical or hippocampal tissue loss, or lateral ventricle swelling. All data is from analysis conducted 20 weeks post-hNSC transplantation/vehicle injection. long-term (≥ 2 months) studies are necessary to fully examine longlasting therapeutic efficacy and to ensure that any behavioral gains are due to treatment and not spontaneous recovery (Nudo, 1999; Gold et al., 2013) . Furthermore, the need for long-term studies is particularly important when the therapy being evaluated involves the transplantation of human neural stem cells that may require several weeks-tomonths to integrate and mature in vivo.
Therefore, we first characterized a battery of potential long-term cognitive behavioral impairments following TBI in immunodeficient ATN rats. This is the first report of these measures in ATN rats using a controlled cortical impact (CCI) model of TBI. In this study, immunodeficient ATN rats demonstrated hippocampal-dependent spatial memory deficits at 2-3 months post-injury (NPR, MWM), thus confirming that cognitive deficits that are typically present after TBI in common immunosufficient animal strains are also present after TBI in immunodeficient ATN rats and persist for several months after injury. However, the same brain-injured animals did not demonstrate long-term cognitive impairment on either a non-spatial memory task (NOR) or on measures that test anxiety or emotional memory (EPM, CTA). Interestingly, previous studies have reported cognitive impairment after TBI on non-spatial memory or anxiety measures (Gold et al., 2013) . However, the majority of these studies did not evaluate cognitive behavior at long-term (≥2 months) time points after injury. Of the few studies that did evaluate behavior at time points N 2 months post-injury, one group reported EPM and Forced Swim impairments that were shown to persist until 2 months post-injury (Shultz et al., 2012; Shultz et al., 2013) , and in a second set of studies, Forced Swim and Passive Avoidance impairments were present up to 2-3 months post-TBI (Milman et al., 2005; Milman et al., 2008) . In each of these studies, however, the injuries were generated by diffuse methods (Lateral Fluid Percussion Injury and Weight-Drop, respectively). Conversely, our injury paradigm (CCI) generates a more focal injury in which brain regions critical for non-spatial or anxiety/emotional-related memory may not have been damaged to the same extent found in studies utilizing other injury methods, thereby generating shorter-lasting impairment. However, the alternative possibility that such memory deficits never existed from the outset in our study must also be considered as we only performed cognitive assessments at later time points.
Evaluating the effects of hNSC transplantation on cognitive recovery following TBI
To evaluate the potential for hNSC transplant-mediated cognitive improvement post-TBI, hippocampal-dependent spatial memory was When compared to sham animals, significant neuronal loss is present in vehicle injected TBI animals in both the (B) injured DG (two-tailed t-test t5 = 9.76, P b 0.001) and (C) injured CA (two-tailed t-test t5 = 12.29, P b 0.0001). When compared to vehicle injected TBI animals, transplantation of high passage (P27) Shef6 hNSCs prevents neuronal loss in both the (B) injured DG (two-tailed t-test t9 = 2.33, P b 0.05) and (C) injured CA (two-tailed t-test t9 = 2.49, P b 0.05). Transplantation of low passage (P7) Shef6 hNSCs had no effect on neuronal survival after TBI in either region. (D-E) Linear regression analysis revealed significant positive correlations between (D) host DG cell survival and NPR score (Pearson r = 0.70, P = 0.0003, one-tailed t-test) and (E) host CA cell survival and NPR score (Pearson r = 0.64, P = 0.001, one-tailed t-test). All data is from analysis conducted 20 weeks posthNSC transplantation/vehicle injection. # represents comparisons made to sham animals. *represents comparisons made between groups. #/*P b 0.05, ##/**P b 0.01, ###/***P b 0.001. Data are presented as mean ± s.e.m. measured. Previous studies have shown efficacy for the transplantation of both murine (Riess et al., 2002; Schouten et al., 2004; Bakshi et al., 2006) and human neural cell types (discussed below) in ameliorating cognitive dysfunction after TBI, including the transplantation of fetal human neural stem/progenitor cells (Hagan et al., 2003; Al Nimer et al., 2004; Wennersten et al., 2004; Gao et al., 2006; Wennersten et al., 2006; Skardelly et al., 2011; Poltavtseva et al., 2012; Wang et al., 2012) and human NT2N neurons (Muir et al., 1999; Critically however, only one of these studies evaluated cognitive function long-term (2 or more months) after injury and human neural cell transplantation and reported improvement on a cognitive measure (Skardelly et al., 2011) , further demonstrating the need for more longterm cognitive behavioral studies to be conducted in the future. Additionally, the findings from many TBI and stem cell transplantation studies are based on methods that may be too heterogeneous to facilitate direct comparisons between studies and in some cases, publication bias may be present as larger studies with higher Quality Index (QI) scores often have smaller effect sizes than small studies with low QI scores (Chang et al., 2015) .
While recent studies have reported the successful engraftment and survival of human pluripotent-derived stem cells in rodent models of TBI, including the demonstration of human induced pluripotent stem cell (hiPSC) derived NSC engraftment and cell tracking (Tang et al., 2013) as well as the first demonstration of successful hESC-derived oligodendrocyte progenitor cell (OPC) engraftment in an ATN TBI model (Xu et al., 2015) , to our knowledge, zero studies to date have been conducted assessing the effects of hESC-NSC transplantation in modulating cognitive function after TBI. Our study therefore is the first demonstration of hESC-NSC transplant-mediated recovery of cognitive function post-TBI. ATN TBI animals transplanted with hNSCs demonstrated significant improvement on both the NPR and MWM tasks. However, the MWM improvement was observed only in the reversal phase and also only when learning slopes were analyzed, not latency to platform. The reversal phase of MWM is considered to be more challenging than acquisition as it requires animals to both extinguish a previously learned location and then learn a new one (Vorhees and Williams, 2006) . Multiple examples exist where experimental animals show little to no differences during acquisition but exhibit strong deficits during reversal (Vorhees and Williams, 2014) , particularly in the case of hippocampal damage. In our MWM reversal assessment, sham animals from the outset quickly learned the new platform location. However, all ATN TBI animals took considerably longer, suggesting a slower learning process. By looking then at learning slopes, we can observe that ATN TBI animals given vehicle only never demonstrate any improvement (zero slope) during reversal testing.
Conversely, ATN TBI animals transplanted with hNSCs do demonstrate improvement (negative slope), and their rate of learning (slope) is nearly identical to that of sham animals. Together with the improvement observed on the NPR task, these data suggest an overall net positive effect on cognitive improvement post-TBI in animals transplanted with hNSCs.
Evaluating the effects of hNSC transplantation on histological outcome measures following TBI
In this study, unbiased stereological methods were used to quantify the effect hNSC transplantation has on modulating histological measures such as lesion volume, spared cortical and hippocampal tissue volume, ventricle volume, and host hippocampal neuron survival. Very few studies have assessed the effects that human fetal neural progenitor (Skardelly et al., 2011) or NT2N neuron (Philips et al., 2001; Vaysse et al., 2015) transplantation has on reducing lesion volume and/or increasing host neuronal survival. Skardelly et al., found that human fetal progenitor cell transplantation decreased lesion size as measured by T2-weighted MRI at 2.5 months post-injury/cell transplantation and also increased neuronal survival at 3 months post-injury/cell transplantation in the cortex adjacent to the site of injury. However, as only motor related behavioral impairments were measured, not cognition, hippocampal neuron survival was not assessed. Additionally, Philips et al. reported an increase in hippocampal CA3 pyramidal cell survival after NT2N neuron transplantation. However, this effect was measured only 1 day after cell transplantation; whether this improvement persisted long-term is unknown. Finally, Vaysse et al. recently .6% ± 4.1; Shef6 P7, n = 6, 37.6% ± 2.0; Shef6 P27 vs. Shef6 P7, two-tailed t-test t9 = 4.36, P b 0.01), (C-D) GFAP+ astrocytes (Shef6 P27, n = 4, 13.2% ± 3.4; Shef6 P7, n = 6, 15.8% ± 3.2), and (E-F) Olig2+ oligodendrocytes (Shef6 P27, n = 5, 11.3% ± 1.7; Shef6 P7, n = 6, 13.1% ± 2.5), or remain (G-H) undifferentiated and express Nestin (Shef6 P27, n = 5, 9.7% ± 6.3; Shef6 P7, n = 6, 23.9% ± 5.3). For all images, red channel represents SC121+ (human) cells. Green channel represents specified cell fate. White arrows indicate examples of colocalized cells. Scale bars = 15 μm (40× images) or 6 μm (100× images). All data is from analysis conducted 20 weeks post-hNSC transplantation/vehicle injection. **P b 0.01. Data are presented as mean ± s.e.m.
found a decrease in lesion size and increased tissue sparing after injection of a biomaterial scaffold seeded with hNT2 neurons, but this assessment was by qualitative measures only. Furthermore, while all of these studies demonstrated improvement in some behavioral measures, no analysis of the potential associations between behavioral improvement and decreased lesion volumes or increased neuronal survival after cell transplantation were performed.
To determine if persistent histological changes occur after transplantation of hNSCs into an immunodeficient rat model of TBI, we first assessed lesion volume (as well as spared cortical and hippocampal tissue volume and ventricle volume) stereologically. Our results indicate that at 5 months post-transplantation, an approximately 60 mm 3 lesion existed in all ATN TBI animals, regardless of whether given vehicle injection or transplanted with hNSCs. One possibility for why no difference was found in hNSC transplanted animals could have been that the injury itself in our study was too severe and the damaged caused by the initial insult was beyond repair. However, pilot studies in our lab revealed that this level of injury was necessary in order for ATNs to develop persistent long-term cognitive deficits. Two other possibilities could be that 1) the delayed nature of our cell transplantation paradigm (hNSCs transplanted 9 days post-injury) did not allow for an early enough intervention to prevent or modulate the initial postinjury wave of damage, and/or that 2) the transplantation of hNSCs into the hemisphere contralateral to injury (as was done in our study) did not allow for the transplanted cells to directly participate in events occurring within or adjacent to the forming lesion.
However, we hypothesized that maximizing transplanted cell survival was of greater importance to behavioral recovery than minimizing lesion size or tissue loss, and previous studies have implicated both transplantation timing as well as location in regards to transplanted cell survival. Analysis of murine NSCs transplanted 2, 7, and 14 days post-TBI demonstrated that cells transplanted at 7 days post-TBI exhibited the highest degree of cell survival (Shear et al., 2011) . This finding is in line with previous speculation that 9 days post-injury in the CNS is the optimal time for cell transplantation (Okano et al., 2003; Nakamura and Okano, 2013) . However, we have previously compared graft survival of hNSCs transplanted into various rodent models of contusion spinal cord injury at 9, 30 and 60 days post-injury and have found that the timing of transplantation doesn't appear to limit cell survival (Cummings et al., 2005; Hooshmand et al., 2009; Salazar et al., 2010; Piltti et al., 2013b) . However, both the differentiation potential and migration patterns of transplanted hNSCs were affected, suggesting that transplantation timing should be given careful consideration when designing future studies. Transplant location also appears to play a role in cell survival, although definitive conclusions remain controversial. Human fetal neural stem cells, when transplanted into either an injured spinal cord environment compared to uninjured spinal cord (Sontag et al., 2014) , or into the injury epicenter compared to locations rostral/caudal to injury (Piltti et al., 2013a) , exhibited decreased survival, suggesting that the injury microenvironment may be prohibitive to transplanted cell survival. Conversely, murine NSCs transplanted into the injured hemisphere after mild TBI exhibited increased survival compared to cells transplanted into the contralateral (uninjured) hemisphere (Shear et al., 2011) . However, considering the source of the NSCs used in our study (human) and the injury severity (moderate/severe), we chose to transplant the hNSCs 9 days post-TBI into the hemisphere contralateral to TBI in an attempt to maximize the potential for transplanted cell survival and behavioral recovery. Ultimately, even though no differences were found in either lesion size or cortical/hippocampal tissue volume due to hNSC transplantation, cognition was still rescued in hNSC transplanted ATN TBI animals, highlighting that restorative TBI therapies need not necessarily focus primarily on reducing lesion size or tissue loss.
Given then that cognitive improvement was found in the absence of reduced lesion volume or increased cortical/hippocampal tissue volume after hNSC transplantation in ATN TBI animals, host hippocampal neuron survival was assessed to determine if differences existed between vehicle and hNSC transplanted animals at the cellular level that could account for the observed behavioral improvement. Previous studies have found that the rodent hippocampus is particularly vulnerable to TBI McCullers et al., 2002; Anderson et al., 2005; Hall et al., 2005) , and there is longstanding evidence for cognitive deficits in rodents with hippocampal neuronal cell loss (Volpe et al., 1992; Conrad and Roy, 1993) . In these studies, lesions to specific hippocampal subregions or surgical procedures that result in region specific hippocampal neuron loss, including neuronal loss in the DG and CA1 regions, caused subsequent memory impairment. Additionally, similar findings have been demonstrated in genetic models of hippocampal neuronal loss (Yamasaki et al., 2007; Myczek et al., 2014) , accelerated aging models (Li et al., 2013) , models of epilepsy (Silva et al., 2013) , early life stress (Brunson et al., 2001) , ischemic stroke (Kirino, 1982; Hartman et al., 2005) , and TBI (Hicks et al., 1993; Scheff et al., 1997 Scheff et al., , 2005 Lu et al., 2007) . Considering that a loss of hippocampal neurons results in cognitive decline, the reverse may be true in that preventing this loss could lead to cognitive improvement. In our study, we found a significant decrease in hippocampal neurons in both the dentate gyrus (DG, 46% decrease) and cornu ammonis (CA, 62% decrease) zones of ATN TBI animals given vehicle injection that was largely prevented by the transplantation of high passage Shef6 hNSCs. Furthermore, significant positive relationships were found between hippocampal DG and CA number with behavioral improvement on the NPR task, suggesting that a possible link exists between increased hippocampal neuron number and improvement in cognitive function after TBI.
However, even though hNSC transplanted animals exhibited increased hippocampal neuronal sparing and cognitive behavioral improvement, caution should still be exercised to not over-interpret this relationship as causal in the absence of data demonstrating a direct link. Additionally, potential mechanisms for behavioral improvement beyond increased hippocampal neuron survival likely also exist as the extent of behavioral recovery in this study was not complete. Furthermore, the question of whether cell integration, trophic support, or possibly immune modulation is ultimately responsible for histological and behavioral improvement remains to be determined. As a first step towards elucidating possible histological correlates to behavioral recovery in this study, we assessed hippocampal neuron survival due to its established relationship with spatial memory. However, our model of TBI also produces significant cortical damage, which has been suggested to play an important (Brutkowski, 1965; Kolb, 1984) but controversial (Nudo, 1999) role in cognition following injury or lesion, but we have yet to evaluate in great detail cortical function after TBI and hNSC transplantation. Future studies will therefore need to assess in greater detail the extent to which stem cell transplantation, and, perhaps importantly, long-term transplanted cell survival contributes to improved host histopathological outcome to determine more precisely the mechanism(s) of action leading to behavioral recovery.
Assessing transplanted hNSC survival, fate, and migration
To determine the extent to which the transplanted hNSCs survived long-term (5 months) after TBI, we quantified human cell survival stereologically. Previously, the same population of CD133 +/CD34 − Shef6 hNSCs utilized in this present study were transplanted into immunodeficient NOD-scid mice and did not exhibit any evidence of non-neural differentiation at 12-weeks post-transplant (Haus et al., 2014) . However, due to the lengthened duration of this present study (20-weeks post-transplant), high passage (P27) Shef6 hNSCs were transplanted in addition to low passage (P7) Shef6 hNSCs in the event that low passage hNSCs were not fully neuralized so as to avoid the potential for teratoma formation (Seminatore et al., 2010) . Additionally, previous evidence suggests that the potential for teratoma formation from transplanted embryonic stem cells may be increased in the presence of an innate inflammatory response (Chen et al., 2014b ) that would likely be found following TBI and stem cell transplantation, which further argues for the use of long-term cultured, stable hNSC lines. Historically, transplanted human cell survival in immunosufficient animal models of CNS injury and disease (for example, studies using C57Bl6 mice or Sprague Dawley rats) has been shown to be quite poor, even when immunosuppressive drugs were administered (Anderson et al., 2011) . In the TBI field to date, only two studies have quantified the number of surviving transplanted human neural cells (Hagan et al., 2003; Wennersten et al., 2006) . Both studies reported the terminal amount of surviving human cells to be b1% of the original transplant dose. In our study, which utilized immunodeficient ATN rats as the host, we observed greatly improved transplanted human cell survival (9-25%), although not as robust as observed with fetal hNSC transplants into spinal cord injured ATN rats (Piltti et al., 2013a) . Interestingly, we found that high passage hNSCs, which appear to have a greater beneficial effect in facilitating behavioral recovery compared to low passage hNSCs and also resulted in greater host hippocampal neuron survival, survived to a lesser extent than low passage hNSCs (9% vs. 25%, respectively). These findings suggest that even though b10% of the original dose of high passage hNSCs survived long-term, these cells were still able to exert a promising beneficial effect on cognitive recovery after TBI. However, the question of whether a higher number of cells survived initially and were slowly lost over time, or if only a small amount survived initially and remained throughout the course of the study, still has yet to be answered.
Interestingly, a previous study using this same hNSC cell population demonstrated a neuronal fate preference both in vitro and after transplantation into an uninjured immunodeficient host (Haus et al., 2014) . Additionally, the transplanted hNSCs exhibited limited migration away from the transplant site. However, in the present study, in response to injury, transplanted hNSCs exhibited a broader differentiation profile and also migrated to a greater extent than in the naïve host. We examined transplanted hNSC fate and found that while the highest percentage of hNSCs still differentiated into NeuN + neurons (19-38%), astrocyte (13-16%) and oligodendrocyte (11-13%) differentiation readily occurred. Additionally, a significant percentage of cells appeared to remain undifferentiated and continued to express Nestin (10-24%) even after 20 weeks of in vivo maturation. These findings suggest that not just one cell type (for example: neurons) may be important for facilitating cognitive recovery after TBI.
3D reconstructions and regional quantification of transplanted cell survival demonstrate that many cells migrate away from the transplant site, with some even entering the contralateral (injured) hemisphere and others migrating to the more ventral aspects of the hippocampus and cortex. A recent study published by Xu et al., reporting for the first time the use of ATN rats in a TBI/cell transplantation model, demonstrated contralateral migration of transplanted hESC-derived OPCs after TBI (Xu et al., 2015) , providing further evidence of the migratory potential of human pluripotent-derived stem cells when transplanted after injury. In the clinical setting, transplanted cell migration will likely be a very important consideration. By having a cell population that is migratory, patients will require fewer injections. In our study, we have transplanted cells into 4 different sites (3 total needle tracts) in the hemisphere contralateral to the injury. The location of the transplantation sites was chosen to maximize transplanted cell health (by injecting them distal to the injury site) and also to maximize the potential for transplanted cell migration (by injecting them into the corpus callosum). Our finding that TBI animals receiving hNSC injections in this manner demonstrated improved cognitive function compared to TBI animals receiving vehicle injection supports the effectiveness of this approach. However, even though many of the transplanted hNSCs in our study did exhibit migration away from the injection site, a significant portion remained in adjacent areas, demonstrating the need for further improvements to be made in enhancing the migration of transplanted pluripotent-derived hNSCs.
Conclusions
In summary, we have shown that hippocampal-dependent spatial memory impairments exist in an immunodeficient ATN model of cortical impact TBI, and that these impairments persist long-term (N2-3 months) . Furthermore, we have demonstrated that in this model of TBI, transplanted hNSCs survive to a greater extent compared to previous TBI xenotransplantation studies utilizing immunosufficient animals given immunosuppressive drugs, and that transplantation of hNSCs restores cognitive function after TBI. Importantly, recovery of cognitive function was achieved without large-scale modifications of lesion or spared tissue volume, suggesting that therapies aimed at improving cognition after brain injury do not necessarily need to prevent tissue loss or reduce lesion volume. Instead, the focus could be centered on modulating the microenvironment within the surviving host tissue to increase, for example, hippocampal neuron survival, which in this study was found to be associated with improved cognitive behavioral recovery. Additionally, some evaluated measures of behavioral recovery, but not all, were improved in this study with the survival of only 9-25% of transplanted hNSCs, suggesting the possibility that further cognitive improvement might be possible if a greater percentage of transplanted human cells survive. Future studies will need to be conducted to evaluate whether increasing the transplantation dose, and thereby potentially increasing the amount of surviving transplanted cells, will lead to further cognitive gains. Additionally, transplantation of different cell types, including fetal-and iPS-derived hNSCs, should also be evaluated in order to determine if an optimal cell population exists to aide in the recovery of cognitive function after TBI.
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